Intestinal Alkaline Phosphatase in Stool: A Novel Biomarker for Metabolic Diseases
| Autor: | Jean-Paul Lallès |
|---|---|
| Přispěvatelé: | Alimentation Adaptations Digestives, Nerveuse et Comportementales (ADNC), Institut National de la Recherche Agronomique (INRA), Centre de Recherche en Nutrition Humaine |
| Rok vydání: | 2015 |
| Předmět: |
Male
L-Arg L-homoarginine viruses BMI body mass index IAP-KO IAP knockout TNAP tissue non-specific alkaline phosphatase lcsh:Medicine Gut flora Systemic inflammation commentaire Feces 0302 clinical medicine Intestinal mucosa Risk Factors Intestinal Mucosa IAP intestinal alkaline phosphatase ComputingMilieux_MISCELLANEOUS 2. Zero hunger 0303 health sciences lcsh:R5-920 biology Incipient diabetes General Medicine Middle Aged insulino- résistance 3. Good health Intestines AP alkaline phosphatase Hypertension 030211 gastroenterology & hepatology Female medicine.symptom biological phenomena cell phenomena and immunity lcsh:Medicine (General) biomarqueur Research Article Autre (Sciences du Vivant) Adult musculoskeletal diseases medicine.medical_specialty [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT] Context (language use) General Biochemistry Genetics and Molecular Biology 03 medical and health sciences Insulin resistance Metabolic Diseases Internal medicine Diabetes mellitus Fatty liver medicine phosphatase alcaline Humans FPG fasting plasma glucose Obesity Glucose intolerance Malo 030304 developmental biology Aged lcsh:R biology.organism_classification medicine.disease Alkaline Phosphatase maladie métabolique Enzyme Activation body regions Endocrinology Diabetes Mellitus Type 2 l-Phe l-phenylalanine Case-Control Studies Commentary LPS lipopolysaccharides The metabolic syndrome Metabolic syndrome Biomarkers |
| Zdroj: | EBioMedicine 12 (2), 1866. (2015) EBioMedicine EBioMedicine, Elsevier, 2015, 2 (12), pp.1866. ⟨10.1016/j.ebiom.2015.12.001⟩ EBioMedicine, Vol 2, Iss 12, p 1866 (2015) |
| ISSN: | 2352-3964 |
| DOI: | 10.1016/j.ebiom.2015.12.001 |
| Popis: | Mice deficient in intestinal alkaline phosphatase (IAP) develop type 2 diabetes mellitus (T2DM). We hypothesized that a high level of IAP might be protective against T2DM in humans. We determined IAP levels in the stools of 202 diabetic patients and 445 healthy non-diabetic control people. We found that compared to controls, T2DM patients have approx. 50% less IAP (mean +/− SEM: 67.4 +/− 3.2 vs 35.3 +/− 2.5 U/g stool, respectively; p Graphical abstract Highlights • Diabetes patients have very low levels of intestinal alkaline phosphatase (IAP) in their stool. • Obese people with high IAP do not develop diabetes. • A low level of IAP in a healthy person is indicative of having the incipient (latent) metabolic syndrome (diabetes). • Approximately 65% of the healthy population have the incipient metabolic syndrome including incipient diabetes. • ‘Temporal IAP profiling’ should diagnose the incipient metabolic syndrome (diabetes). Currently, diabetes is diagnosed by high blood sugar, for example having fasting plasma glucose (FPG) > 7.0 mmol/l. High FPG is associated only with already established diabetes, and therefore FPG cannot predict years in advance whether a person have incipient (latent) diabetes. This study shows that diabetes patients have very low levels of the gut enzyme intestinal alkaline phosphatase (IAP) in their stool indicating a protective role of IAP against diabetes. Even obese people do not develop diabetes if their IAP levels are high. Approx. 65% of healthy people have low IAP suggesting that these people have the incipient (latent) metabolic syndrome including incipient diabetes, and are very vulnerable to develop diabetes and other metabolic disorders in the near future. The study suggests that regular monitoring of stool IAP (temporal IAP profiling) might be very helpful to diagnose ‘incipient’ diabetes, the metabolic syndrome and other metabolic disorders. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|